UNITED STATES INTERNATIONAL TRADE COMMISSION

Washington, D.C.

In the Matter of **CERTAIN PRE-FILLED SYRINGES FOR INTRAVITREAL INJECTION AND COMPONENTS THEREOF**	**INV. NO. 337-TA-1207**

ORDER NO. 20: MODIFYING THE PROCEDURAL SCHEDULE

(December 10, 2020)

On December 9, 2020, complainants Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC (collectively, "Novartis") and respondent Regeneron Pharmaceuticals, Inc. ("Regeneron") filed a joint motion ("Mot.") seeking to modify certain dates in the procedural schedule issued as Order No. 8 on August 17, 2020. Motion Docket No. 1207-017. The Commission Investigative Staff does not oppose the requested relief. *See* Mot. at 1.

Unopposed Motion No. 1207-017 is granted. The remainder of this investigation shall be conducted in accordance with the following schedule:

Event	Date
Fact discovery cutoff and completion	December 18, 2020
Deadline for final contentions on issues for which the party bears the burden of proof	*December 23, 2020*[1]
Deadline for final contentions on issues for which the party does not bear the burden of proof	*December 23, 2020*
Deadline for motions to compel discovery	*December 29, 2020*

[1] Dates that differ from those set forth in Order No. 8 are indicated by italic typeface.

Event	Date
Monthly case management conference	**January 14, 2021 at 10:30 a.m.**
Exchange initial expert reports (identify tests/surveys/data)	*January 22, 2021*
Exchange rebuttal expert reports	*February 5, 2021*
One-day mediation session	By February 10, 2021
Monthly case management conference	**February 18, 2021 at 10:30 a.m.**
Deadline for filing summary determination motions	February 18, 2021
Expert discovery cutoff and completion	*February 22, 2021*
Exchange of exhibit lists among the parties of proposed direct exhibits	*February 24, 2021*
Complainant and respondent serve proposed direct exhibits, and identify physical exhibits[2]	March 2, 2021
Submit joint report on mediation	*March 3, 2021*
Staff serves proposed direct exhibits, and identifies physical exhibits	March 5, 2021
Serve proposed rebuttal exhibits, and identify rebuttal physical exhibits	March 9, 2021
Complainants and respondent file pre-trial statements and briefs	March 12, 2021
Monthly case management conference	**March 18, 2021 at 10:30 a.m.**
File joint list of unopposed exhibits	March 23, 2021
Staff files pre-trial statement and brief	March 26, 2021
Deadline for motions *in limine*	March 31, 2021

[2] The parties represent they will separately stipulate as to a schedule for exchanging direct and rebuttal demonstratives and objections in the event of live testimony at the evidentiary hearing.

Event	Date
Deadline for responses to motions *in limine*	April 8, 2021
Final pre-hearing conference	**April 16, 2021 at 9:00 a.m.**
Hearing	**April 19-23, 2021 at 9:00 a.m.**
File final exhibit list	April 29, 2021
Complainant and respondent file post-hearing initial briefs with the Secretary and submit final exhibits with the Administrative Law Judge	May 14, 2021
Staff files post-hearing initial brief	May 21, 2021
Complainant and respondent file post-hearing responsive briefs	May 28, 2021
Staff files post-hearing responsive brief	June 4, 2021
Final initial determination	**July 29, 2021**
Target date for completion of investigation	November 29, 2021

SO ORDERED.

Clark S. Cheney
Administrative Law Judge

CERTAIN PRE-FILLED SYRINGES FOR INTRAVITREAL INJECTION AND COMPONENTS THEREOF

Inv. No. 337-TA-1207

PUBLIC CERTIFICATE OF SERVICE

I, Lisa R. Barton, hereby certify that the attached **ORDER** has been served via EDIS upon the Commission Investigative Attorney, **W. Peter Guarnieri, Esq.**, and the following parties as indicated, on **December 11, 2020.**

Lisa R. Barton, Secretary
U.S. International Trade Commission
500 E Street, SW, Room 112
Washington, DC 20436

On Behalf of Complainants Novartis Pharma AG, Novartis Pharmaceuticals Corporation, and Novartis Technology LLC:

Elizabeth J. Holland, Esq.
GOODWIN PROCTER LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018
Email: EHolland@goodwinlaw.com

☐ Via Hand Delivery
☐ Via Express Delivery
☐ Via First Class Mail
☒ Other: Email Notification of Availability for Download

On Behalf of Respondent Regeneron Pharmaceuticals, Inc.:

Anish R. Desai, Esq.
WEIL, GOTSHAL & MANGES LLP
767 5th Avenue
New York, NY 10153
Email: anish.desai@weil.com

☐ Via Hand Delivery
☐ Via Express Delivery
☐ Via First Class Mail
☒ Other: Email Notification of Availability for Download